| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| Targets |
GSK-3β
|
|---|---|
| ln Vitro |
In IBV Beaudette-infected BHK cells, lithium chloride hydrate (5 and 20 mM, 36 hours) reduces cytopathic effects and IBV replication [1]. IBV-induced apoptosis and inflammation in BHK cells are inhibited by lithium chloride hydrate (5 and 20 mM, 36 hours) [1]. The efficiency of neurospheres produced from induced pluripotent stem cells is increased by lithium chloride hydrate (1 mg/mL) [4]. PC12 cells are shielded against apoptosis caused by morphine (HY-P1701) by lithium chloride hydrate (1.2 mM, 72 hours) [5].
|
| ln Vivo |
Rats' sevoflurane (SEV)-induced memory impairment is ameliorated by lithium chloride hydrate (60 mg/kg, ip, twice daily) [2]. In rats undergoing extraction socket repair, lithium chloride hydrate (150 mg/kg, orally, every other day) promotes bone growth [6].
|
| Cell Assay |
RT-PCR[1]
Cell Types: BHK cells Tested Concentrations: 5 and 20 mM Incubation Duration: 36 h Experimental Results: Blocked the expression of NF-κB, NLRP3, TNF-α, and IL-1β. Blocked levels of Caspase-3, Bax and increased Bcl-2 level. |
| Animal Protocol |
Animal/Disease Models: Rats[5]
Doses: 150 mg/kg Route of Administration: Oral administration (po), every other day Experimental Results: Produced greater proportion of newly formed bone (NB). Lowered the rate of TRAP-stained cells. Animal/Disease Models: Sevoflurane-induced memory impairment rats[2] Doses: 60 mg/kg Route of Administration: intraperitoneal (ip)injection, twice a day. Experimental Results: diminished escape latency, increased time in the objective quadrant and raised platform crossings. Suppresses SEV-induced oxidative stress reduces and diminished SEV-induced apoptosis in the hippocampus. |
| References |
|
| Molecular Formula |
LICL.XH2O
|
|---|---|
| Molecular Weight |
42.39 (anhydrous basis)
|
| Exact Mass |
59.995
|
| CAS # |
85144-11-2
|
| PubChem CID |
23681138
|
| Appearance |
White to off-white solid powder
|
| Density |
1.21 g/mL at 20 °C
|
| Boiling Point |
1382 °C
|
| Melting Point |
605 °C(lit.)
|
| Flash Point |
-4 °F
|
| Index of Refraction |
n20/D 1.381
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
3
|
| Complexity |
2
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VXJIMUZIBHBWBV-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/ClH.Li.H2O/h1H;;1H2/q;+1;/p-1
|
| Chemical Name |
lithium;chloride;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL
H2O : ≥ 50 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
